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Maternal mRNA expression levels of H19 are inversely 
associated with risk of macrosomia
Hua Jiang1, Yang Yu2, Pengcheng Xun3,4, Jun Zhang2, Guanghua Luo2, Qiuwei Wang1
A b s t r a c t
Introduction: To investigate the associations between the mRNA levels of 
H19 in term placenta and risk of macrosomia.
Material and methods: Term placentas were collected from 37 macroso-
mia and 37 matched neonates with normal birth weight (controls) born in 
Changzhou Women and Children Health Hospital, Jiangsu province, P. R. Chi-
na from March 1 to June 30, 2008. The mRNA levels of H19 in those placen-
tas were measured by real-time polymerase chain reaction (PCR). Simple and 
multiple logistic regression models were used to explore the risk factors in 
the development of macrosomia. All analyses were performed using Stata 
10.0 (StataCorp, College Station, Texas, USA).
Results: The average H19 mRNA level of the macrosomia group was 1.450 
±0.456 while in the control group it was 2.080 ±1.296. Based on the result 
of Student’s t test, there was a  significant difference in H19 mRNA level 
between the macrosomia group and the control group (p = 0.008). After 
controlling for potential confounders, the multivariable adjusted odds ratio 
(OR) of macrosomia for those in the highest tertile of H19 mRNA level was 
0.12 (95% CI: 0.02–0.59) when compared to those in the lowest tertile (p for 
linear trend = 0.009). 
Conclusions: The term placental H19 mRNA levels were inversely related to 
the occurrence of macrosomia. Our findings suggest that the low expression 
of H19 mRNA may contribute to the development of macrosomia.
Key words: macrosomia, placenta, H19, insulin-like growth factor II, real-
time polymerase chain reaction.
Introduction
Overweight and obesity have increased tremendously during the 
past 10–15 years and have become a global health problem. The preva-
lence of overweight and obesity in Chinese adults has increased two- to 
three-fold in the past 10–15 years [1, 2] and among Chinese children 
and adolescents it has increased steadily from 5.2% in 1991 to 13.2% 
in 2006 [3]. The prevalence of overweight and obesity increased in all 
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age groups, in both rural and urban areas, and 
in North and South China. The overall combined 
prevalence of overweight and obesity was 23.2% 
(17.6% for overweight and 5.6% for obesity) in 
2002 [4].
Macrosomia has been suggested as one of the 
possible risk factors for obesity in many studies 
[5, 6]. Macrosomia was defined as a condition in 
which a neonate has a birth weight (BW) equal to 
or greater than 4000 g. The morbidity of macro-
somia reaches 7–10% [7]. In 2006, the morbidity 
of macrosomia was 6.5% in China [8]. Socioeco-
nomic advances and the improvement in wom-
en’s living standards can predispose to the devel-
opment of fetal macrosomia, which may result in 
childhood obesity [5, 6]. It is a vicious cycle.
The placenta, as the interface between mother 
and fetus, is central to prenatal growth control. 
The fetus is dependent upon the placenta for its 
supply of nutrients and oxygen from the mother. 
Our previous research found that the placental 
weights in the macrosomia group were signifi-
cantly higher than those in the control group and 
placental weight was positively correlated with 
birth weight [9]. Recent evidence suggests that 
imprinted genes may regulate the growth and 
transport capacity of the placenta by controlling 
the supply of nutrients [10].
Imprinted genes are expressed in a  par-
ent-of-origin manner by epigenetic modifications 
that silence either the paternal or maternal allele. 
In general, paternally expressed genes enhance 
feto-placental growth while maternally expressed 
genes limit conceptus growth. Insulin-like growth 
factor II (IGF-II)/H19 is a pair of imprinted genes 
discovered early. They are similarly positioned, 
reciprocally imprinted, their expression being 
correlated with regulation. They co-regulate the 
growth and transport capacity of the placenta, 
thereby controlling the supply of nutrients, and 
are important for fine tuning of normal fetal 
growth.
Studying the risk factors for macrosomia is of 
particular public health importance for its prima-
ry prevention and therefore reducing the morbid-
ity of obesity.
Previous research focused on whether loss of 
imprinting status of IGF-II and H19 existed in the 
placentas of congenital growth disorders such 
as Beckwith-Wiedemann (BWS) [11], Silver-Rus-
sell (SRS) syndromes [12], fetal growth restric-
tion (FGR) [13] and pre-eclampsia [14]. But there 
has been little research concerning the relation 
between the expression of IGF-II and H19 and 
these diseases. However, imprinting status may 
not be associated with the RNA level [15]. So, it 
is inconclusive how IGF-II and H19 work: through 
altering the imprinting status? Changing the RNA 
level? Or both? Our previous research found that 
the levels of placental IGF-II were over-expressed 
in macrosomia [9]. Therefore, in this study we will 
further investigate the association between the 
expression of H19 in the placenta and the occur-
rence of macrosomia.
Material and methods
This is a case-control study of the association 
between mRNA levels of H19 in the placenta and 
the occurrence of macrosomia. The study was ap-
proved by the human research ethics committees 
of the Changzhou Women and Children’s Health 
Hospital.
Subjects
Thirty-seven macrosomia cases were chosen 
randomly from 116 cases found among children 
born in Changzhou Women and Children Health 
Hospital from March 1 to June 30, 2008. Macroso-
mia was defined as a condition in which neona-
tes had a  BW equal to or greater than 4000 g. 
Thirty-seven neonates with normal BW in the 
corresponding period were chosen as controls. 
Mothers of both groups had no diabetes or oth-
er complications during pregnancy, confirmed by 
negative results of a 75 g oral glucose tolerance 
test in the 24th–28th week of pregnancy. 
Biomarker detection
A piece of villus tissue 1 cm × 1 cm × 1 cm in 
size was collected from the center of the placenta 
under aseptic conditions within 5 min after the 
delivery of the placenta. Then the specimen was 
cleansed with normal saline (NS) and preserved 
in liquid nitrogen with Frozen Pipe.
The primers and probes were designed by 
Primer Premier 5.0 according to the sequence of 
GAPDH, IGF-II and H19 genes (GenBank accession 
number NM_002046, J03242 and AK092486, re-
spectively) and synthesized at Shanghai Sangon 
Biological Engineering Technology and Services 
Co., LTD. The standard samples of each gene were 
ordered from Shanghai Shenyou Biological Tech-
nology Co., LTD. The sequences of primers and 
probes are displayed in Table I.
Tissue general RNA was gathered according to 
steps described in the manual of general RNA ex-
traction kit. 2 µg of general RNA was gathered from 
every tissue. Reverse transcription reaction was 
done in the qualitative PCR device. All real-time 
PCR reactions were done on the ABI 7300 re-
al-time PCR device. Complex control was done on 
every specimen. A standard sample was involved 
in every reaction. The PCR reaction system was 
composed of: 10 × PBS 2.5 µl, 25 mmol/l MgC12 
1.5 µl, 10 mmol/l 4 × dNTPs 0.5 µl, 100 µmol/l Jus-
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tice primer 0.1 µl, 100 µmol/l anti-sense primer 
0.1 µl, 100 µmol/l probe 0.1 µl, 5 U/µl Taq enzyme 
0.25 µl, specimen 2 µl. Polymerase chain reaction 
(PCR) water level was kept at 25 µl. Reaction con-
ditions went through the following steps: prede-
generation at 95°C for 1 min, then degeneration 
at 95°C for 5  s, extension of the annealing at 
60°C for 30 s (collection of fluorescent signal at 
this step) and enlarged to 40 cycles. The stan-
dard sample was (diluted by 10 times of con-
centration gradient (108–103)), and a  threshold 
cycle (CT) value standard curve was drawn on 
the concentration logs of all standard samples. 
The CT value was defined as the cycle number 
when a fluorescent signal was registered in the 
reaction tube when a set threshold was reached. 
Then the start copy number was calculated from 
the standard curve in accordance with the CT 
value of the unknown specimen.
Covariates
Information about pregnant women’s age, 
height, education level, weight before pregnancy, 
weight gain during pregnancy, duration of preg-
nancy, and time of delivery were collected using 
an interviewer-administered questionnaire.
Statistical analysis
Group comparisons of basic characteristics were 
performed using Student’s t test or Wilcoxon’s 
z  test as appropriate. Pearson’s or Spearman’s 
rank correlation coefficients between indi cators 
were calculated depending on the distributions 
of the variables. H19 expression levels were di-
vided into three groups according to their tertiles, 
with the lowest tertile as the reference. Multiple 
logistic regression models were used to explore 
the association between H19 levels and the oc-
currence of macrosomia.
All analyses were performed using Stata 10.0 
(StataCorp, College Station, Texas, USA). Value 
of p ≤ 0.05 was considered statistically signif-
icant.
Results
General characteristics of the two groups
The average BW of the macrosomia group was 
4175.8 ±178.7 g while the control group BW was 
3230.0 ±303.5  g. The macrosomia group had 
a higher BMI before pregnancy, higher maternal 
weight before pregnancy and higher weight gain 
during pregnant. There were no significant dif-
ferences between cases and controls in maternal 
age, maternal height, paternal height, paternal 
weight, paternal BMI, pregnant days or gestation-
al weeks between the two groups (Table II). No 
significant differences were found in mothers’ ed-
ucation level (Wilcoxon’s z = –1.161, p = 0.246), 
family income (z = 0.763, p = 0.445), or gender of 
the baby (z = –0.256, p = 0.798).
Levels of IGF-II and H19 in the placenta
The level of IGF-II showed a positively skewed 
distribution; therefore, median and inter-quartile 
ranges (Q1-Q3) were used to describe the data. 
The level of H19 was normally distributed; there-
fore, mean and standard deviation were used to 
describe the data. The levels of IGF-II and H19 
expression in placenta of macrosomia and con-
trol groups are shown in Table III. Based on the 
results of Wilcoxon’s z test and Student’s t test, 
there were significant differences in IGF-II mRNA 
and H19 mRNA level between the macrosomia 
group and the control group.
Correlation between levels of IGF-II  
and H19 in the placenta
Spearman rank correlation analysis suggested 
that the level of IGF-II had a linear upward trend 
along with the increase of the H19 in the nor-
mal birth weight group (r = 0.34, p = 0.04), while 
Table I. Sequences of PCR primers and specific probe (5′- 3′) for the detection of GAPDH, IGF-II and H19 by real- 
time PCR 
Primer Sequence
GAPDH Sense primer GGA AGG TGA AGG TCG GAG TC
Antisense primer CGT TCT CAG CCT TGA CGG T
Probe FAM-TTT GGT CGT ATT GGG CGC CTG-TAMRA
IGF-II Sense primer CGG CTT CTA CTT CAG CAG GC
Antisense primer TGG CGG GGG TAG CAC AGT
Probe FAM-CAA GCC GTG TGA GCC GTC GCA-TAMRA
H19 Sense primer CAG AAC CCA CAA CAT GAA AGA AAT 
Antisense primer TCA GGT AGT GCA GTG GTT GTA AAG T 
Probe FAM-AAG CCT GGG CCT TTG AAT CCG GAC A-TAMRA  
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there was no correlation in the macrosomia group 
(r = 0.19, p = 0.25).
Association between H19 levels and risk  
of macrosomia 
We categorized exposures of interest into ter-
tiles. The initial analysis (model 1) was an unad-
justed model. In model 2, we adjusted for mater-
nal height (continuous), maternal weight before 
pregnancy (continuous) and weight gain during 
pregnancy (continuous), and in model 3 we ad-
ditionally adjusted for IGF-II (tertiles). Continu-
ous variables were used for linear trend tests. As 
compared with those in the lowest tertile of H19 
mRNA level, the multivariable adjusted odds ratio 
(OR) of macrosomia was 0.22 (95% CI: 0.05–0.89) 
(p for linear trend = 0.033) for those in the highest 
tertile (model 2). When further adjusted for IGF-II 
levels (tertiles), the inverse association was a lit-
tle strengthened (OR = 0.12 (95% CI: 0.02–0.59); 
p for linear trend = 0.009) (Table IV).
Discussion
Our research showed that the level of H19 in 
the placenta in macrosomia was significantly low-
er than that of control group. There was a positive 
correlation between the levels of IGF-II and H19 
in the placenta in normal birth weight. The H19 
Table II. Basic characteristics of pregnant women*
Parameter Macrosomia† Normal birth weight Value of p‡
No. of participants 37 37
Maternal age [years] 27.95 ±3.3 27.22 ±3.04 0.33
Maternal height 162.65 161.22 0.18
Maternal weight before pregnancy 56.20 52.30 0.01
BMI before pregnancy§ 21.22 ±2.36 20.15 ±1.58 0.03
Weight gain during pregnancy [kg] 20.50 ±4.34 17.20 ±4.78 < 0.01
Paternal height 174.08 172.89 0.28
Paternal weight 70.62 69.97 0.79
Paternal BMI 23.07 23.37 0.71
Pregnant days 278.86 ±6.36 276.35±4.79 0.06
*Plus-minus values are mean ± SD. †Macrosomia is defined as neonates with birth weight ≥ 4000 g. ‡Difference between groups was 
tested by Student’s t test. §BMI – body mass index, which is the weight in kilograms divided by the square of the height in meters
Table III. Levels of insulin growth factor-II (IGF-II) and H19 in maternal placenta between groups
Group No. of participants IGF-II mRNA H19 mRNA
Median Q1–Q3* Mean SD
Macrosomia† 37 2.53 2.18–4.30 1.45 0.46
Normal birth weight 37 1.70 0.87–3.55 2.08 1.30
Value of p‡ 0.03* < 0.01*
*Q1–Q3 denotes inter-quartile range. †Macrosomia is defined as neonates with birth weight ≥ 4000 g. ‡Difference between groups was 
tested by Wilcoxon’s rank sum test and Student’s t test





Model I† Model II‡ Model III§
Tertile 1 15 10 1.00 (Referent) 1.00 (Referent) 1.00 (Referent)
Tertile 2 15 10 1.00 (0.32–3.10) 1.12 (0.31–4.02) 1.29 (0.31–5.38)
Tertile 3 7 17 0.27 (0.08–0.90) 0.22 (0.05–0.89) 0.12 (0.02–0.59)
P for linear trend|| 0.033 0.033 0.009
*All the models were constructed by using logistic regression models. Macrosomia was defined as neonates with birth weight ≥ 4000 g. 
†Model I: unadjusted model. ‡Model II: Adjusted for maternal height (continuous), maternal weight before pregnancy and weight gain 
during pregnancy (continuous). §Model III: additionally adjusted for IGF-II (tertiles). ||Continuous variables were used for the linear trend tests
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mRNA in the placenta was inversely associated 
with the occurrence of macrosomia.
The relation between H19 and IGF-II  
in placenta and the growth of placenta  
and macrosomia
Previous studies on macrosomia mainly dis-
cussed gestational nutrition. However, the regu-
latory function of the placenta is also important. 
The imprinted genes IGF-II and H19 are crucial 
for placental development and fetal growth [10]. 
The IGF-II gene is paternally expressed and the 
H19 gene is maternally expressed. Most of the re-
search paid close attention to whether loss of im-
printing of IGF-II and H19 existed in the placentas 
of pregnancy-related complications [13–18]. There 
was loss of imprinting of H19 in the placentas of 
fetal growth restriction [13, 17] and pre-eclampsia 
patients [14, 15]. There was no loss of genomic 
imprinting of IGF-II and H19 in placentas of dia-
betic pregnancies with fetal macrosomia [18].
It was suggested that imprinting status did not 
agree with the RNA level [15]. Therefore, we de-
tected the levels of IGF-II mRNA and H19 mRNA in 
the placenta to explore whether there was alter-
ation of IGF-II and H19 RNA levels in the macroso-
mia placenta. 
Our research showed that placental expression 
levels of IGF-II were significantly increased in the 
macrosomia group (p = 0.025) [9], while levels of 
H19 were significantly reduced (p = 0.008). The 
over-expression of IGF-II mRNA in the placenta 
was confirmed as an independent risk factor of 
macrosomia indicated by both single and multiple 
logistic regression analysis. The high expression 
of H19 mRNA in the placenta was confirmed as 
an independent protective factor of macrosomia 
(OR = 0.12, 95% CI: 0.02–0.59).
H19 is a maternally expressed gene that lim-
its conceptus growth. Hence, low expression of 
H19 may be connected with the placenta in the 
macrosomia group more than the control group. 
In a study of intrauterine growth restriction, pla-
cental expression levels of H19 were found to be 
significantly increased in the FGR group [19]. This 
is consistent with the hypothesis that low expres-
sion of H19 mRNA contributes to macrosomia.
The IGF-II is a paternally expressed gene that 
enhance feto-placental growth. It was reported 
that reduced fetal size in IGF-II knockout mice 
was accompanied by changes in the morpholog-
ical features and also the size of the placentas in 
these animals [20, 21]. Sibley reported further that 
IGF-II affected not only the placental development 
but also the placental transportation ability using 
a knockout mice experiment [22]. Thus, it is rea-
sonable to speculate that over-expression of IGF-II 
mRNA contributes to macrosomia.
Factors influencing the level of H19  
in the placenta 
Expression of imprinted genes is classically as-
sociated with differential methylation of specific 
CpG-rich DNA regions (DMR). A methylated DMR 
on the paternal chromosome inactivates adjacent 
H19 and an unmethylated DMR on the maternal 
chromosome insulates IGF-II from the enhancers.
In a  pathophysiological study of preeclamptic, 
data from methylation-sensitive high resolution 
melting demonstrated hypermethylation of the 
promoter region of the H19 gene, and results of 
real-time PCR showed decreased mRNA expression 
of the H19 gene in early-onset preeclamptic pla-
centas as compared with the normal controls [23].
However, in a pathophysiological study of fetal 
growth restriction (FGR), placentas from growth-re-
stricted pregnancies had lower methylation levels 
compared to normals, in the H19 promoter region. 
Placental expression levels of H19 were signifi-
cantly increased in the FGR group [19]. The hy-
pomethylation of the H19 promoters is compatible 
with the aberrant expression.
The over-expression of IGF-II could be caused 
by deletion or knockout of H19 [24], while loss of 
imprinting and hence biallelic expression could 
downregulate the expression of IGF-II [25]. It is still 
unclear whether alteration of the H19 level could 
regulate directly the expression of IGF-II mRNA and 
whether the level of H19 mRNA in the macrosomia 
placenta is involved in regulation of its methyla-
tion, which needs to be further investigated.
The mechanisms of these genes’ effects on 
macrosomia will be the focus of our continual 
study. In view of the factors that may affect the 
expression of imprinted genes, the methylation of 
DMR of imprinted genes is most critical. The key 
of our next study project will be to determine the 
methylation status of certain CpG islands in the 
control region on the genomic DNA. 
In conclusion, the significant positive associ-
ations between the level of placental IGF-II and 
H19 and macrosomia were explored. Our findings 
suggest that a  potential risk effect of the value 
of the expression of IGF-II mRNA and H19 mRNA 
in the placenta may exist during the development 
of macrosomia. Further studies are warranted 
to confirm our findings and clarify the potential 
mechanisms.
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